Biopharmaceutical News and Research

RSS

Expression Genetics completes phase I trial of lead drug candidate, EGEN-001

Expression Genetics, Inc., has announced the completion of a Phase I clinical study evaluating the Company's lead drug candidate, EGEN-001.

17 Apr 2007

Use of computer-assisted drug design in drug discovery

Metabasis Therapeutics has announced that on March 27, 2007 at the American Chemical Society 233rd National Meeting and Exposition in Chicago, Dr. M. Rami Reddy presented, "Use of Computer-Assisted Drug Design in Drug Discovery: Limitations and Advantages of Available Computational Methods."

15 Apr 2007

Intarcia Therapeutics announces results from study of injectable Omega Interferon plus Ribavirin for treatment of hepatitis C genotype-1

Intarcia Therapeutics has announced final results from a Phase 2 study of omega interferon with or without ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C.

15 Apr 2007

Coley Pharmaceutical licenses VaxImmune to Merck

Coley Pharmaceutical Group has announced that Merck & Co has licensed Coley's VaxImmune vaccine adjuvant for incorporation into vaccines being developed by Merck for certain infectious diseases and Alzheimer's disease.

15 Apr 2007

BioMed Realty Trust embarks on $145 million expansion at Eastview

BioMed Realty Trust Breaks Ground on $145 Million Lab and Office Complex at The Landmark at Eastview

15 Apr 2007

Avista Capital acquires BioReliance from Invitrogen

Avista Capital Partners has announced it has completed its acquisition of BioReliance Corporation, a business unit of Invitrogen Corporation for approximately $210 million.

15 Apr 2007

Abbott agrees with WHO to expand access to lopinavir / ritonavir

Abbott and World Health Organization (WHO) Director-General, Margaret Chan, have agreed on a balanced approach to provide Kaletra/Aluvia (lopinavir/ritonavir) capsules and tablets to more patients in the developing world, while supporting continued long-term biopharmaceutical research and development.

10 Apr 2007

New target for diagnosis and treatment of ovarian cancer

An RNA-binding protein that is overproduced in ovarian cancer may present a new target for diagnosis or treatment of ovarian and other cancers, according to researchers at the University of Illinois at Chicago.

10 Apr 2007

Alteon expands agreement with Biorap Technologies

Alteon has announced that it has entered into an expanded licensing agreement with BioRap Technologies, the commercialization arm of the Rappaport Family Institute for Research, Technion University, Israel, for all diagnostic devices or products for predictive purposes in vascular or cardiac diseases, including diagnostic assays for the measurement of the haptoglobin protein (Hp).

7 Apr 2007

Natural mechanism for immune suppression may lead to new cancer drugs

A natural mechanism pirated by tumors and HIV to evade the immune response is opening the door to better treatment for these conditions, researchers say.

31 Mar 2007

Legislation introduced that would give FDA authority to approve generic versions of biotechnology drugs

Lawmakers in the House and Senate on Wednesday introduced a bill that would allow FDA to approve generic versions of biotechnology medications, USA Today reports.

19 Feb 2007

New hope for women with Alzheimer's disease

Leuprolide acetate helps women with mild-to-moderate Alzheimer's disease maintain functional capabilities for a longer period of time, according to data presented Monday by Voyager Pharmaceutical Corporation.

18 Jul 2006

University of Florida and France sign cooperative four-year research agreement

The University of Florida and two biomedical institutes in France have signed a four-year cooperative agreement on biopharmaceutical research that is designed to help bring new therapies to clinical trials.

11 Jul 2006

Majority of sexual assaults drug facilitated

Almost 62 percent of sexual assaults were found to be drug facilitated, and almost 5 percent of the victims were given classic 'date-rape' drugs, according to a new study at the University of Illinois at Chicago.

11 May 2006

First gene therapy human trial in the United States for a form of muscular dystrophy under way

The clinical trial for Duchenne muscular dystrophy (DMD) tests the safety and effectiveness of a therapy that was developed over two decades by scientists at the University of North Carolina Chapel Hill's School of Medicine and the University of Pittsburgh.

16 Apr 2006

Single dose of stem cells produce robust behavioral recovery in animal models for stroke, cerebral palsy

A single dose of adult donor stem cells given to animals that have neurological damage similar to that experienced by adults with a stroke or newborns with cerebral palsy can significantly enhance recovery from these types of injuries, researchers say.

11 Apr 2006

Discovery of compound that reduces hallmark lesions of Alzheimer's disease in mice

Researchers at UC Irvine have found that a new compound not only relieves the cognitive symptoms of Alzheimer's disease, but also reduces the two types of brain lesions that are hallmarks of this devastating disease, thereby blocking its progression.

7 Mar 2006

Patent losses open up $30 billion biologics market to generic competition

With powerhouse biologics, such as human growth hormone and insulin, losing their U.S. patent protection in 2005 and many more set to expire within the next 4 years, generic competition in the lucrative biopharmaceutical market is imminent, according to a new study from Kalorama Information.

25 Jan 2006

New anthrax antibody

A new anthrax antibody engineered by scientists at The University of Texas at Austin protects and defends against inhalation anthrax without the use of antibiotics and other more expensive antibodies.

2 Dec 2005

Ospemifine may also help to prevent breast cancer

A tamoxifen-like drug developed by UC Davis and Finnish researchers, now in clinical testing as a treatment for vaginal atrophy, may also help to prevent breast cancer, two preliminary studies suggest.

3 Nov 2005